Abstract

Motivation: This research addresses a critical gap by investigating the impact of depression treatment on neurometabolites in the PCC. Goal(s): This exploratory study aims to investigate the relationship between neurometabolite levels in the PCC and assess its impact on treatment. Approach: Structural MRI and MRS data were acquired from 16 MDD patients and 16 healthy controls. The concentration of neurometabolites was quantified. ANOVA models were used to assess differences between groups. Results: Treatment effectively reduced depressive symptoms but did not significantly alter neurometabolite levels in the PCC. Factors such as medication, small sample size, and short follow-up intervals may have contributed to these results. Impact: This research highlights that, despite effective treatment response in improving depressive symptoms in MDD patients, neurometabolite levels in the PCC were not significantly altered, emphasizing the necessity for further, more extensive research to comprehensively understand MDD and its treatment.